On June 27, 2025, the Pujiang Prostate Cancer Academic Congress was held in Shanghai, in conjunction with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Meeting of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Meeting of the Chinese Prostate Cancer Consortium (CPCC). The event gathered leading experts from around the world to discuss cutting-edge developments in prostate cancer treatment. Professor Lu Yang, Department of Urology, West China Hospital of Sichuan University, delivered a keynote presentation on recent advances in targeting the androgen receptor (AR) pathway in prostate cancer, providing important insights for clinical decision-making. He offered a comprehensive overview of the latest innovations in monotherapy, emerging evidence from combination strategies, and the translational potential of new technologies such as PROTACs and epigenetic modulators—while also addressing current challenges and future directions.

As the tides of the Pujiang River surge forward, so too does China's momentum in prostate cancer innovation. The 2025 Pujiang Prostate Cancer Academic Congress—held jointly with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai from June 27–28. The event gathered leading experts from China and abroad to exchange the latest advances and clinical practices in prostate cancer. In an exclusive interview with Oncology Frontier – Urology Frontier, Congress Chair and Professor Dingwei Ye of Fudan University Shanghai Cancer Center shared his perspectives on the current status and future of prostate cancer care in China, along with recent innovations in surgical treatment.

The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,” the event brought together leading domestic and international experts to share cutting-edge progress and clinical experience in prostate cancer. During the conference, Professor Xiaojie Bian of Fudan University Shanghai Cancer Center spoke with Oncology Frontier – Urology Frontier to discuss the current landscape and future prospects of innovative drug development for prostate cancer.